Indian pharmaceutical major Zydus Lifesciences Limited (NSE:ZYDUSLIFE) has announced the acquisition of Assertio Holdings Inc. (NASDAQ:ASRT) in an all-cash deal valued at nearly ₹1,600 crore ($166.4 million).
Under the agreement, Zydus will acquire all outstanding shares of Assertio at $23.50 per share through a tender offer followed by a merger process. Once completed, Assertio will be delisted from Nasdaq, marking another major step in Zydus’ global expansion strategy.
The acquisition is expected to significantly strengthen Zydus’ footprint in the US specialty and oncology-focused pharmaceutical markets.
Strategic Push into High-Value US Markets
The deal provides Zydus access to an established specialty product portfolio, commercial infrastructure, and physician networks in the United States — the world’s largest pharmaceutical market.
Industry analysts believe the acquisition aligns with Zydus’ long-term strategy of moving beyond traditional generics into specialty therapies, biosimilars, and complex formulations that offer stronger margins and sustainable growth opportunities.
Assertio’s commercial presence could also help Zydus accelerate launches of future specialty and pain-management products in the US market.
Zydus Financial Performance Remains Strong
Zydus has continued to deliver robust operational growth across its global businesses. According to the company’s Q3 FY26 investor presentation, revenue from operations rose 30% year-on-year to ₹68,645 million, while EBITDA increased 31% to ₹18,164 million.
The company reported adjusted net profit of ₹11,109 million during Q3 FY26, supported by strong growth across India formulations, North America formulations, and international markets.
Its North America formulations business contributed nearly 41% of revenue and recorded 16.4% year-on-year growth during the quarter.
Zydus has also been expanding aggressively in biosimilars, specialty drugs, vaccines, and rare disease therapies, reflecting its transition toward innovation-led growth.
Strong US Business Momentum
The acquisition announcement follows several important developments for Zydus in the US market:
- Multiple ANDA approvals and product launches
- Expansion into biosimilars and oncology therapies
- USFDA approval for rare disease therapy Zycubo®
- Acquisition of biologics manufacturing facilities in California
- Growing investment in specialty pharmaceuticals and MedTech initiatives
The company’s US specialty initiatives and biosimilar pipeline are expected to remain key long-term growth drivers.
Technical Summary
Zydus Lifesciences is trading with a positive bias above its 51-day EMA near ₹918, indicating improving short-term momentum. The stock trading at ₹983.15 after a strong breakout move, while RSI near 65 reflects strengthening buying interest without entering overbought territory yet. Sustained strength above ₹980 may support further upside momentum in the near term.
FAQs
- Why is Zydus acquiring Assertio Holdings?
The acquisition helps Zydus strengthen its specialty pharmaceutical business and expand its commercial presence in the US market.
- How much is the Assertio acquisition deal worth?
The transaction is valued at approximately $166.4 million, or nearly ₹1,600 crore.
- How could the acquisition impact Zydus?
The deal may improve Zydus’ specialty drug portfolio, strengthen margins, and support long-term growth in the US pharmaceutical market.